Narrow search
Showing 1 - 10 of 152
Cover Image
Utilization of healthcare services and renewal of health insurance membership : evidence of adverse selection in Ghana
Duku, Stephen Kwasi Opoku; Asenso-Boadi, Francis; … - In: Health economics review 6 (2016) 43, pp. 1-12
Background: Utilization of healthcare in Ghana’s novel National Health Insurance Scheme (NHIS) has been increasing since inception with associated high claims bill which threatens the scheme’s financial sustainability. This paper investigates the presence of adverse selection by assessing...
Persistent link: https://www.econbiz.de/10011586649
Cover Image
Risk selection into supplemental private health insurance in China
Jiang, Yawen; Ni, Weiyi - In: Health economics review 9 (2019) 36, pp. 1-11
Background: Information on risk selection is important for the regulation and development of supplemental private health insurance (PHI). The research on risk selection into supplemental PHI has been documented in several developed countries where the regulation of the PHI markets was relatively...
Persistent link: https://www.econbiz.de/10012162528
Cover Image
Promoting vaccinations - an analysis of measures taken by German statutory health insurers
Damm, Kathrin; Schubert, Jana M.; Schulenburg, … - In: Health economics review 1 (2011) 16, pp. 1-6
Introduction: Prophylactic vaccinations play a significant role in health care. As a relatively cost-effective preventive measure they can help to avert transmissible diseases and thus protect not only the vaccinated individuals themselves but also those who have not been vaccinated. In order to...
Persistent link: https://www.econbiz.de/10009503925
Cover Image
Competition between health maintenance organizations and nonintegrated health insurance companies in health insurance markets
Baranes, Edmond; Bardey, David - In: Health economics review 5 (2015) 36, pp. 1-9
This article examines a model of competition between two types of health insurer: Health Maintenance Organizations (HMOs) and nonintegrated insurers. HMOs vertically integrate health care providers and pay them at a competitive price, while nonintegrated health insurers work as indemnity plans...
Persistent link: https://www.econbiz.de/10011472211
Cover Image
The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany
Dintsios, C. M.; Beinhauer, I. - In: Health economics review 10 (2020) 7, pp. 1-25
Background: We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price … Health Insurance Funds. The analysis was conducted for all oncology pharmaceuticals that underwent the early benefit …. Further analyses should be performed when more oncology pharmaceuticals have passed the early benefit assessment. …
Persistent link: https://www.econbiz.de/10012291135
Cover Image
The impact of reimbursement negotiations on cost and availability of new pharmaceuticals: evidence from an online experiment
Wettstein, Dominik J.; Boes, Stefan - In: Health economics review 10 (2020) 13, pp. 1-15
Background: The necessity to measure and reward "value for money" of new pharmaceuticals has become central in health … study assesses the impact of a negotiation situation for lifeextending pharmaceuticals on societal outcomes. Of interest …
Persistent link: https://www.econbiz.de/10012291180
Cover Image
Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
Sanchez-de la Rosa, Rainel; Sabater, Eliazar; Casado, … - In: Health economics review 3 (2013) 13, pp. 1-5
Background: Fingolimod is an innovative drug with a significant budget impact in the treatment of MS in Spain. The aim of this study was to calculate the direct cost comparison of glatiramer acetate and fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS)...
Persistent link: https://www.econbiz.de/10009755990
Cover Image
Treatment of type 2 diabetes with saxagliptin : a pharmacoeconomic evaluation in Argentina
Elgart, Jorge F.; Caporale, Joaquin E.; Gonzalez, Lorena; … - In: Health economics review 3 (2013) 11, pp. 1-9
Background: The increasing prevalence of diabetes and its inadequate management results in a heavy burden of the disease for the patients, the health and the productive system and the overall community. Consequently, it is necessary to have new effective drugs to treat people with diabetes to...
Persistent link: https://www.econbiz.de/10009756005
Cover Image
Quantifying the broader economic consequences of quadrivalent human papillomavirus (HPV) vaccination in Germany applying a government perspective framework
Kotsopoulos, Nikolaos; Connolly, Mark P.; Remy, Vanessa - In: Health economics review 5 (2015) 23, pp. 1-11
HPV infections can cause substantial burden in females and males as it is associated with several genital cancers, in addition to genital warts. Traditional economic evaluations often focus on quantifying cost-effectiveness, however, it is increasingly recognized that vaccinations may generate...
Persistent link: https://www.econbiz.de/10011471871
Cover Image
Benefit assessment in Germany : implications for price discounts
Theidel, Ulrike; Schulenburg, Johann-Matthias von der - In: Health economics review 6 (2016) 33, pp. 1-12
Background: The AMNOG regulation, introduced in 2011 in Germany, changed the game for new drugs. Now, the industry is required to submit a dossier to the GBA (the central decision body in the German sickness fund system) to show additional benefit. After granting the magnitude of the additional...
Persistent link: https://www.econbiz.de/10011586599